Home » BARR RECEIVES APPROVAL FOR GENERIC XANAX XR TABLETS
BARR RECEIVES APPROVAL FOR GENERIC XANAX XR TABLETS
Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc., announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.'s XANAX XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg.
The company intends to launch its product immediately.
Yahoo
Finance
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May